Cargando…

Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development

Infection with nontuberculous mycobacteria (NTM) is a complication of lung disease in immunocompromised patients, including those with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The most wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Auster, Lauren, Sutton, Morgan, Gwin, Mary Chandler, Nitkin, Christopher, Bonfield, Tracey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406338/
https://www.ncbi.nlm.nih.gov/pubmed/30717247
http://dx.doi.org/10.3390/microorganisms7020042
_version_ 1783401278279254016
author Auster, Lauren
Sutton, Morgan
Gwin, Mary Chandler
Nitkin, Christopher
Bonfield, Tracey L.
author_facet Auster, Lauren
Sutton, Morgan
Gwin, Mary Chandler
Nitkin, Christopher
Bonfield, Tracey L.
author_sort Auster, Lauren
collection PubMed
description Infection with nontuberculous mycobacteria (NTM) is a complication of lung disease in immunocompromised patients, including those with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The most widespread, disease-causing NTM is Mycobacterium avium complex (MAC), which colonizes the lungs as a combination of Mycobacterium avium, Mycobacterium intracellulare, and other mycobacterial species. While combination drug therapy exists for MAC colonization, there is no cure. Therapeutic development to treat MAC has been difficult because of the slow-growing nature of the bacterial complex, limiting the ability to characterize the bacteria’s growth in response to new therapeutics. The development of a technology that allows observation of both the MAC predominant strains and MAC could provide a means to develop new therapeutics to treat NTM. We have developed a new methodology in which M. avium and M. intracellulare can be optimally grown in short term culture to study each strain independently and in combination, as a monitor of growth kinetics and efficient therapeutic testing protocols.
format Online
Article
Text
id pubmed-6406338
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64063382019-03-26 Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development Auster, Lauren Sutton, Morgan Gwin, Mary Chandler Nitkin, Christopher Bonfield, Tracey L. Microorganisms Article Infection with nontuberculous mycobacteria (NTM) is a complication of lung disease in immunocompromised patients, including those with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The most widespread, disease-causing NTM is Mycobacterium avium complex (MAC), which colonizes the lungs as a combination of Mycobacterium avium, Mycobacterium intracellulare, and other mycobacterial species. While combination drug therapy exists for MAC colonization, there is no cure. Therapeutic development to treat MAC has been difficult because of the slow-growing nature of the bacterial complex, limiting the ability to characterize the bacteria’s growth in response to new therapeutics. The development of a technology that allows observation of both the MAC predominant strains and MAC could provide a means to develop new therapeutics to treat NTM. We have developed a new methodology in which M. avium and M. intracellulare can be optimally grown in short term culture to study each strain independently and in combination, as a monitor of growth kinetics and efficient therapeutic testing protocols. MDPI 2019-02-01 /pmc/articles/PMC6406338/ /pubmed/30717247 http://dx.doi.org/10.3390/microorganisms7020042 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Auster, Lauren
Sutton, Morgan
Gwin, Mary Chandler
Nitkin, Christopher
Bonfield, Tracey L.
Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development
title Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development
title_full Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development
title_fullStr Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development
title_full_unstemmed Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development
title_short Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development
title_sort optimization of in vitro mycobacterium avium and mycobacterium intracellulare growth assays for therapeutic development
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406338/
https://www.ncbi.nlm.nih.gov/pubmed/30717247
http://dx.doi.org/10.3390/microorganisms7020042
work_keys_str_mv AT austerlauren optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment
AT suttonmorgan optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment
AT gwinmarychandler optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment
AT nitkinchristopher optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment
AT bonfieldtraceyl optimizationofinvitromycobacteriumaviumandmycobacteriumintracellularegrowthassaysfortherapeuticdevelopment